118794-10-8Relevant articles and documents
The discovery of potent and selective kynurenine 3-monooxygenase inhibitors for the treatment of acute pancreatitis
Liddle, John,Beaufils, Benjamin,Binnie, Margaret,Bouillot, Anne,Denis, Alexis A.,Hann, Michael M.,Haslam, Carl P.,Holmes, Duncan S.,Hutchinson, Jon P.,Kranz, Michael,McBride, Andrew,Mirguet, Olivier,Mole, Damian J.,Mowat, Christopher G.,Pal, Sandeep,Rowland, Paul,Trottet, Lionel,Uings, Iain J.,Walker, Ann L.,Webster, Scott P.
, p. 2023 - 2028 (2017)
A series of potent, competitive and highly selective kynurenine monooxygenase inhibitors have been discovered via a substrate-based approach for the treatment of acute pancreatitis. The lead compound demonstrated good cellular potency and clear pharmacodynamic activity in vivo.
3-(5-CHLORO-2-OXOBENZO[D]OXAZOL-3(2H)-YL)PROPANOIC ACID DERIVATIVES AS KMO INHIBITORS
-
, (2015/07/07)
A compound of formula (I) or a salt thereof are provided wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.
